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Table 2. Comparison between patients with and without infectious
complications.
Parameters With infections
(n Z 12)
Without
infections
(n Z 11)
P value
Age, years 74.8 5.1 71.3 4.1 0.10a
Male gender, n (%) 3 (25%) 5 (45.5%) 0.40b
Body weight, kg 57.2 12.7 68.5 9.5 0.03a
Hypertension, n (%) 8 (72.7%) 9 (81.8%) 1.00b
Diabetes mellitus, n (%) 2 (16.7%) 0 (0%) 0.48b
Charlson’s Comorbidity
Index score
5.1 1.9 4.1 1.3 0.16a
Baseline serum
creatinine, umol/L
234 (94e545) 116 (57e161) 0.04c
Baseline urine creatinine
clearance, mL/min
23.3 (10.9e57.8) 48 (29e72) 0.10c
Baseline serum albumin, g/L 25 (17e32) 22 (20e24) 0.57c
Non-responder, n (%) 9 (75%) 2 (18.2%) 0.01b
Continuous data is expressed as mean standard deviation or median
(interquartile range)
aComparison by independent sample t test
bComparison by Fisher’s exact test
cComparison by Mann-Whitney test
Azathioprine 5 (21.7%)
Duration on immunosuppressant, months 13.7 (5.7e30.7)
Non-responder to immunosuppressant) 11 (47.8%)
Hospitalization, episodes (days)
Infection-related
Pneumonia 8 (34)
Urinary tract infection 4 (20)
CMV disease 2 (23)
Septicaemia of uncertain origin 4 (284)
Other infections 7 (30)
Cardiovascular / cerebrovascular events 4 (109)
Others 31 (144)
End of follow-up status, n (%)
End-stage kidney disease 4 (17.4%)
Death 5 (21.7%)
Proportion of mortality attributed to infection 3 (60%)
Continuous data expressed as mean standard deviation or median
(interquartile range); CMV Z cytomegalovirus.
)Defined as deteriorating renal function or reduction in proteinuria
<50% from baseline.
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Methods: Sixty-eight IMNpatientswereenrolled inthisprospectivecohort study.
Low dose prednisone and low dose cyclosporine were prescribed on the basis of
renin-angiotensin-aldosterone (RAS) inhibition. Remission rate, relapse rateand
different renal functionchangeprofileswere recorded.Followuprenal endpoint
was defined as a decrease in eGFR >50% from baseline and a development of
eGFR< 60 ml/min/1.73 m2. Risk factors for renal injury were further analysed.
Results: A cyclosporine dose of 2.0 0.5 mg/kg/d and prednisone of
0.33 0.18 mg/kg/d were prescribed. The duration of cyclosporinetreatment was 31 17 months. The follow-up time was 46 20 months.
Twenty-nine patients (43%) achieved complete remission at 15.9 11.8
months, and 33 patients (47%) got partial remission at a median of 6 (range:
1e40) months. Twenty-six out of 62 patients (42%) with remission had relapse.
Fourteen patients (20%) developed cyclosporine-acute renal injury (CsA-ARI)
at 2.5 0.8 months, with SCr increased by > 30% during the first 3 months,
and 16 patients (24%) developed cyclosporine-chronic renal injury (CsA-CRI)
at 7.1 3.0 months with SCr increased by > 30% or eGFR decreased by >
30% during the course of the first year. Proteinuria at the time of CsA-ARI
was indentified as an independent risk factor for CsA-ARI. Lower baseline
eGFR level was identified as independent risk factor for CsA-CRI. At the end
of follow up, 16 patients (24%) reached the renal endpoint. Presence of
intimal fibrosis of artery and higher time-averaged proteinuria were identified
as independent risk factors for renal endpoint. RAS inhibition treatment
decreased the risk of renal endpoint. Neither cyclosporine cumulative usage
time nor cumulative dosage was found to be risk factors for renal injury.
Conclusion: Low dose cyclosporinewas effective in treating nephrotic patients
of IMN. Cyclosporine-associated renal injury should be an important concern
even at this low implemented dosage, especially in lower initial eGFR patients.http://dx.doi.org/10.1016/j.hkjn.2015.09.0330305
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Objective: Insulin-like growth factor I (IGF-I) and insulin-like growth factor II
(IGF-II) are polypeptides regulating growth and cellular proliferation in
humans, and most importantly influence renal parenchyma cells and endo-
thelial cells. IGF-binding protein 3 (IGFBP-3) and IGF-binding protein 5
(IGFBP-5) modify the function of IGFs by binding to them with high-affinity.
This study aimed to investigate the role of IGF-I, IGF-II, IGFBP-3 and IGFBP-5
in adult Henoch-Schoenlein nephritis.
Methods: Serum levels of IGF-I, IGF-II, IGFBP-3 and IGFBP-5 were measured
by ELISA in 50 healthy controls (control group) and 85 adult patients with
Henoch-Schoenlein purpura (HSP group) in which 52 patients with HSPN
(HSPN group) were included. The clinical features, laboratory data and renal
pathological findings of candidates were also analyzed.
Results: Compared to the controls, plasma albumin was significantly
decreased yet serum levels of IgA and IgA/C3 were increased in the HSP
group. The serum levels of IGF-I, IGF-II, IGFBP-3 and IGFBP-5 were signifi-
cantly increased in HSP group compared to the control group (P < 0.001). Pa-
tients with HSPN had higher levels of IGF-I, IGF-IIand IGFBP-3 than HSP
patients without renal damage. In patients with HSP, the serum levels of
IGF-I, IGF-II and IGFBP-3 were related to proteinuria and plasma albumin
positively, and estimated glomerular filtration rate (eGFR) negatively by cor-
relation analysis. Logistic regression modeling confirmed that levels of IGF-I,
IGF-II and IGFBP-3 were positively related to proteinuria after adjustment
for age, albumin and eGFR. By a mean of 42.4 months of follow-up, serum
levels of IGF-I, IGF-II and IGFBP-3 were risk factors for 30% decline in eGFR.
Conclusion: The serum levels of IGF-I, IGF-II and IGFBP-3 could be new
markers to evaluate proteinuria and predict the renal outcomes in adult HSPN.http://dx.doi.org/10.1016/j.hkjn.2015.09.0350306
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The direct renin inhibitor aliskiren displays antihypertensive and antialbu-
minuric effects in humans and in animal models. Emerging evidence has
shown that aliskiren localizes and persists in medullary collecting ducts even
after treatment was discontinued. The purpose of the present study was to
